Combinatorial biosynthesis--potential and problems.

Because of their ecological functions, natural products have been optimized in evolution for interaction with biological systems and receptors. However, they have not necessarily been optimized for other desirable drug properties and thus can often be improved by structural modification. Using examples from the literature, this paper reviews the opportunities for increasing structural diversity among natural products by combinatorial biosynthesis, i.e., the genetic manipulation of biosynthetic pathways. It distinguishes between combinatorial biosynthesis in a narrower sense to generate libraries of modified structures, and metabolic engineering for the targeted formation of specific structural analogs. Some of the problems and limitations encountered with these approaches are also discussed. Work from the author's laboratory on ansamycin antibiotics is presented which illustrates some of the opportunities and limitations.

[1]  J B McAlpine,et al.  Modular organization of genes required for complex polyketide biosynthesis. , 1991, Science.

[2]  H. Floss,et al.  Rifamycin-mode of action, resistance, and biosynthesis. , 2005, Chemical reviews.

[3]  Jie Yang,et al.  Natural product glycorandomization. , 2004, Bioorganic & medicinal chemistry.

[4]  D. Guénard,et al.  Chemical studies of 10-deacetyl baccatin III: Hemisynthesis of taxol derivatives , 1986 .

[5]  T. Mahmud,et al.  Identification of tailoring genes involved in the modification of the polyketide backbone of rifamycin B by Amycolatopsis mediterranei S699. , 2005, Microbiology.

[6]  H. Ikeda,et al.  Production of ‘hybrid’ antibiotics by genetic engineering , 1985, Nature.

[7]  A. Bechthold,et al.  It works: combinatorial biosynthesis for generating novel glycosylated compounds , 2005, Molecular microbiology.

[8]  M. Egorin,et al.  Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats , 2001, Cancer Chemotherapy and Pharmacology.

[9]  B. Wilkinson,et al.  Combinatorial biosynthesis of polyketides and nonribosomal peptides. , 2001, Current opinion in chemical biology.

[10]  L. Chung,et al.  The FK520 gene cluster of Streptomyces hygroscopicus var. ascomyceticus (ATCC 14891) contains genes for biosynthesis of unusual polyketide extender units. , 2000, Gene.

[11]  D. Macneil,et al.  Production of the antitumor drug epirubicin (4′-epidoxorubicin) and its precursor by a genetically engineered strain of Streptomyces peucetius , 1998, Nature Biotechnology.

[12]  N. Kedersha,et al.  Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  W. Evans.  Biochemistry of the bacterial catabolism of aromatic compounds in anaerobic environments , 1977, Nature.

[14]  P. Margalith,et al.  Rifomycin, a new antibiotic; preliminary report. , 1959, Il Farmaco; edizione scientifica.

[15]  János Bérdy,et al.  Bioactive microbial metabolites. , 2005, The Journal of antibiotics.

[16]  L. Bai,et al.  Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. , 2002, Journal of the American Chemical Society.

[17]  P. Wiley,et al.  Erythromycin. X.1 Structure of Erythromycin , 1957 .

[18]  T. Hasegawa,et al.  Ansamitocin, a group of novel maytansinoid antibiotics with antitumour properties from Nocardia , 1977, Nature.

[19]  J. Staunton.  1.19 – Biosynthesis of Erythromycin and Related Macrolides , 1999 .

[20]  Yaoquan Liu,et al.  A New Substrate Specificity for Acyl Transferase Domains of the Ascomycin Polyketide Synthase in Streptomyces hygroscopicus * , 2002, The Journal of Biological Chemistry.

[21]  C. Walsh,et al.  The loading module of rifamycin synthetase is an adenylation-thiolation didomain with substrate tolerance for substituted benzoates. , 2001, Biochemistry.

[22]  Linquan Bai,et al.  Functional expression of genes involved in the biosynthesis of the novel polyketide chain extension unit, methoxymalonyl-acyl carrier protein, and engineered biosynthesis of 2-desmethyl-2-methoxy-6-deoxyerythronolide B. , 2002, Journal of the American Chemical Society.

[23]  S. Shah,et al.  Immunoconjugates containing novel maytansinoids: promising anticancer drugs. , 1992, Cancer research.

[24]  S. Akiyama,et al.  Fermentative production and biosynthesis of ansamitocins. Part I. Selective accumulation of ansamitocins P-2,P-3 and P-4, and biosynthetic origins of their acyl moieties. , 1984 .

[25]  D. Hopwood,et al.  Molecular cloning of the whole biosynthetic pathway of a Streptomyces antibiotic and its expression in a heterologous host , 1984, Nature.

[26]  Modification of post-PKS tailoring steps through combinatorial biosynthesis. , 2002, Natural product reports.

[27]  K. Chater,et al.  Production of 8'-halogenated and 8'-unsubstituted novobiocin derivatives in genetically engineered streptomyces coelicolor strains. , 2004, Chemistry & biology.

[28]  H. H. Mills,et al.  THE STRUCTURE AND STEREOCHEMISTRY OF ERYTHROMYCIN A. , 1965, Tetrahedron letters.

[29]  Chaitan Khosla,et al.  PRIMER UNIT SPECIFICITY IN RIFAMYCIN BIOSYNTHESIS PRINCIPALLY RESIDES IN THE LATER STAGES OF THE BIOSYNTHETIC PATHWAY , 1998 .

[30]  B. Moore,et al.  Direct evidence that the rifamycin polyketide synthase assembles polyketide chains processively. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Kenneth K. Chan,et al.  Recent developments in the maytansinoid antitumor agents. , 2004, Chemical & pharmaceutical bulletin.

[32]  H. Leuenberger,et al.  Preparation of dry powder inhalation by surface treatment of lactose carrier particles. , 2003, Chemical & pharmaceutical bulletin.

[33]  C. Gustafsson,et al.  Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  H. Floss,et al.  3-Amino-5-hydroxybenzoic Acid Synthase, the Terminal Enzyme in the Formation of the Precursor of mC7N Units in Rifamycin and Related Antibiotics* , 1998, The Journal of Biological Chemistry.

[35]  C. Walsh.  Combinatorial Biosynthesis of Antibiotics: Challenges and Opportunities , 2002, Chembiochem : a European journal of chemical biology.

[36]  Cloning and sequence analysis of the putative rifamycin polyketide synthase gene cluster from Amycolatopsis mediterranei. , 1998, FEMS microbiology letters.

[37]  R. Traber,et al.  Intermediates of rifamycin polyketide synthase produced by an Amycolatopsis mediterranei mutant with inactivated rifF gene. , 1999, Microbiology.

[38]  C. Hutchinson,et al.  Macrolide biosynthesis. Tylactone formation involves the processive addition of three carbon units , 1987 .

[39]  M. Grever,et al.  Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent , 2004, Cancer Chemotherapy and Pharmacology.

[40]  D. Cane,et al.  Macrolide biosynthesis. 4. Intact incorporation of a chain-elongation intermediate into erythromycin. , 1987 .

[41]  C R Hutchinson,et al.  Biosynthesis of the ansamycin antibiotic rifamycin: deductions from the molecular analysis of the rif biosynthetic gene cluster of Amycolatopsis mediterranei S699. , 1998, Chemistry & biology.

[42]  C. Gilmore,et al.  Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. , 1972, Journal of the American Chemical Society.

[43]  K. Rinehart,et al.  Preparation of four new antibiotics from a mutant of Streptomyces fradiae. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[44]  B. Rawlings.  Type I polyketide biosynthesis in bacteria (Part A--erythromycin biosynthesis). , 2001, Natural product reports.

[45]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[46]  L. Bai,et al.  The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Reeves.  The Enzymology of Combinatorial Biosynthesis , 2003, Critical reviews in biotechnology.

[48]  H. Zähner,et al.  Stoffwechselprodukte von Actinomyceten. 9. Mitteilung. Granaticin , 1957 .

[49]  L. Bai,et al.  The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. , 2003, Journal of the American Chemical Society.

[50]  L. Bai,et al.  Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. , 2002, Journal of the American Chemical Society.

[51]  K. Hasuda,et al.  A new antibiotic, medermycin. , 1976, The Journal of antibiotics.

[52]  C. Deboer,et al.  Geldanamycin, a new antibiotic. , 1970, The Journal of antibiotics.